RNA delivery to the corneal endothelium using charge-altering releasable transporters
Open Access
- 21 August 2026
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Abstract
RNA therapies hold tremendous promise for treating genetic eye diseases. However, their development is limited by the lack of non-viral delivery platforms that can target specific ocular cell types. Here, we describe a charge-altering releasable transporter (CART) that delivers RNA selectively to the corneal endothelium, a non-regenerative cell layer whose dysfunction underlies several blinding conditions. We characterize the safety of CART-RNA nanoparticles in mice and show that they facilitate delivery of diverse RNA cargoes to the corneal endothelium, including circular RNA and CRISPR/Cas9. We verify that these nanoparticles can be redosed and apply them to achieve corneal gene editing. We further demonstrate CART transfection of corneal endothelial cells from a human donor in vitro and in a non-human primate in vivo, supporting the feasibility of clinical translation. Our findings establish CARTs as a platform for non-viral gene delivery to the eye, with the potential to treat corneal dystrophies and other vision disorders.Keywords
Funding Information
- National Institutes of Health (R01-CA245533)
- National Institutes of Health (T32-EY027816)
- National Institutes of Health (R01-CA245533)
- Howard Hughes Medical Institute
- Knights Templar Eye Foundation
- Stanford RNA Medicine Program
- Stanford Center for Molecular Analysis and Design
This publication has 86 references indexed in Scilit:
- Optimization of method for achieving a single-cell suspension from mouse corneasExperimental Eye Research, 2023
- Corneal Wound Healing Effects of Mesenchymal Stem Cell Secretome Delivered Within a Viscoelastic Gel CarrierStem Cells Translational Medicine, 2019
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome EditingCell Reports, 2018
- Systemic Messenger RNA Therapy as a Treatment for Methylmalonic AcidemiaCell Reports, 2017
- Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNAAngewandte Chemie International Edition, 2016
- Global Survey of Corneal Transplantation and Eye BankingJAMA Ophthalmology, 2016
- Cytokines and chemokines: At the crossroads of cell signalling and inflammatory diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- TRIM79α, an Interferon-Stimulated Gene Product, Restricts Tick-Borne Encephalitis Virus Replication by Degrading the Viral RNA PolymeraseCell Host & Microbe, 2011
- Bioengineering endothelialized neo-corneas using donor-derived corneal endothelial cells and decellularized corneal stromaBiomaterials, 2010
- Toxicity of cationic lipids and cationic polymers in gene deliveryJournal of Controlled Release, 2006